DWC 202211
Alternative Names: DWC-202211Latest Information Update: 03 Feb 2023
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 03 Feb 2023 DWC 202211 is available for licensing as of 03 Feb 2023. https://www.daewoong.com/en/company/location/4/view
- 03 Feb 2023 Preclinical trials in Unspecified in South Korea (unspecified route)
- 03 Feb 2023 Daewoong Pharmaceutical plans a phase I pharmacokinetic/pharmacodynamic drug-drug interaction trial (In Volunteers) in South Korea by mid of February 2023 (NCT05699070)